CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The More Medicines for Tuberculosis project focuses on developing new treatments for tuberculosis by screening natural and synthetic compounds. It combines academic research with pharmaceutical expertise to identify effective drug candidates through innovative screening and testing methods.
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule.
Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment.
An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with…
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
India, BANGALORE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Sweden, Uppsala
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Pavia
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom, Cambridge
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
